Atara Biotherapeutics (NASDAQ:ATRA) Cut to In-Line at Evercore ISI

Evercore ISI downgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from an outperform rating to an in-line rating in a research note published on Thursday, MarketBeat.com reports.

Several other analysts also recently commented on the company. Mizuho downgraded Atara Biotherapeutics from a buy rating to a neutral rating in a research note on Thursday. StockNews.com upgraded Atara Biotherapeutics from a sell rating to a hold rating in a report on Thursday, November 2nd. Finally, HC Wainwright cut Atara Biotherapeutics from a buy rating to a neutral rating in a report on Thursday. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Atara Biotherapeutics presently has a consensus rating of Hold and a consensus price target of $28.00.

Atara Biotherapeutics Trading Down 4.2 %

Shares of Atara Biotherapeutics stock opened at $0.23 on Thursday. The company has a market capitalization of $23.42 million, a PE ratio of -0.08 and a beta of 0.98. Atara Biotherapeutics has a 12 month low of $0.21 and a 12 month high of $5.64. The stock’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $1.78.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.03). The business had revenue of $2.14 million for the quarter, compared to analyst estimates of $2.20 million. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 6,390.31%. Analysts predict that Atara Biotherapeutics will post -2.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Pascal Touchon sold 30,766 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $1.65, for a total value of $50,763.90. Following the completion of the transaction, the chief executive officer now owns 675,905 shares in the company, valued at approximately $1,115,243.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 47,624 shares of company stock worth $78,580. Corporate insiders own 4.50% of the company’s stock.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds have recently modified their holdings of the stock. Point72 Hong Kong Ltd grew its holdings in Atara Biotherapeutics by 343.8% during the first quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 5,604 shares during the period. Tower Research Capital LLC TRC grew its holdings in Atara Biotherapeutics by 334.0% during the first quarter. Tower Research Capital LLC TRC now owns 9,041 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 6,958 shares during the period. Two Sigma Investments LP bought a new position in Atara Biotherapeutics during the third quarter worth about $45,000. Envestnet Asset Management Inc. bought a new position in Atara Biotherapeutics during the first quarter worth about $112,000. Finally, Quantbot Technologies LP bought a new position in Atara Biotherapeutics during the second quarter worth about $106,000. Institutional investors own 88.79% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.